Dr Naomi Dempsey explains how she decides on an appropriate CDK4/6 inhibitor for patients receiving first-line treatment for metastatic HR+/HER- breast cancer.
The panel explains how treatment experience with CDK4/6 inhibitors varies for patients with HR+/HER- breast cancer, and which agents are best tolerated.
The annual awards for quirky scientific research were given out this week, and as usual, they blended the bizarre, humorous, and unexpectedly insightful.
The 33rd annual Ig Nobel Prizes in improbable research that make people “LAUGH, then THINK,” according to its website, were revealed this week. The awards are produced by the Annals of Improbable Research magazine.